Table 5 Summary of base model and special sensitivity analysis results
From: An economic model of long-term use of celecoxib in patients with osteoarthritis
Model features | No age risks | Sensitivity analyses with age risks |
|---|---|---|
Lifetime models | Â | Â |
Base model | $31,097 | $19,309 |
Alternative treatments after UGI events models | $38,807–$46,192 | $26,201–$31,777 |
CV thromboembolic risks 1[15] | $17,120 | $7,923 |
Other analytic horizons | Â | Â |
1 year | $124,100 | $124,100 |
5 years | $108,549 | $104,104 |
8 years | $93,420 | $85,534 |
11 years | $67,812 | $58,459 |
12 years | $61,191 | $51,521 |